Croda International has delivered record sales, margin and profit in the first six months of 2022.
Sales for the East Yorkshire-headquartered FTSE-listed smart science specialist were up 20 per cent, from £934 million to £1.1 billion. Operating profits increased 32 per cent from £218 million to £288 million.
It comes as the business has moved away from industrial markets to focus on consumer care, with major expansions in its vaccination-aiding lipid production on both sides of the Atlantic. It has been a key part of the protection against Covid, though the market is described as moderating, and also used in therapeutic drugs, carrying the active ingredient into the body.
